UK watchdog says it may accept remedies in $35 billion Synopsys-Ansys deal

Published 01/08/2025, 06:16 AM
Updated 01/08/2025, 12:52 PM
© Reuters. The headquarters of Synopsys Inc., in Sunnyvale, California, U.S., October 23, 2024. REUTERS/Stephen Nellis/File Photo
ANSS
-
SNPS
-

(Reuters) -The UK's competition regulator said on Wednesday it might accept remedies offered by chip design software maker Synopsys (NASDAQ:SNPS) and Ansys (NASDAQ:ANSS) to address the concerns raised over their $35 billion deal.

Synopsys announced its cash-and-stock deal for Ansys, whose software is used to make products ranging from airplanes to tennis rackets, in January last year.

The Competition and Markets Authority said the undertakings offered on Dec. 31 included the divestment of Ansys' power consumption analysis product for digital chips and Synopsys' sale of its global optics and photonics software business.

© Reuters. The headquarters of Synopsys Inc., in Sunnyvale, California, U.S., October 23, 2024. REUTERS/Stephen Nellis/File Photo

The CMA said it has until March 5 to decide whether to accept the undertakings, with the possibility to extend the deadline to May 6.

A Synopsys spokesperson said the companies are pleased with the regulator's decision, adding that the duo will maintain its "constructive and collaborative engagement" with the CMA.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.